{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:24:29Z","timestamp":1790033069390,"version":"4.0.1"},"reference-count":45,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T00:00:00Z","timestamp":1735603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"JSPS KAKENHI","doi-asserted-by":"publisher","award":["JP23K07373"],"award-info":[{"award-number":["JP23K07373"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Achieving HBsAg seroclearance is a key goal in treating chronic hepatitis B virus (HBV) infection but remains difficult with nucleos(t)ide analogues (NAs). Tenofovir alafenamide fumarate (TAF), a recommended NA for managing chronic HBV infection (CHB), has uncertain effects on HBsAg levels and potential adverse events when used long-term after switching from entecavir (ETV). We retrospectively evaluated 77 CHB patients, including 47 who switched from ETV to TAF with a median follow-up of 40 months post-switch and a median of 60 months of HBsAg monitoring pre-switch. No significant change in HBsAg levels was observed in the overall cohort post-switch, consistent with the ETV continuation group. However, a significant decrease in HBsAg was noted in patients with HBsAg &lt; 100 IU\/mL at the time of switching. HBsAg loss occurred in three patients who switched to TAF. No adverse effects were observed, and TAF was well tolerated. The most significant factor associated with achieving HBsAg &lt; 100 IU\/mL was the Fib-4 index, a marker of liver fibrosis, at the time of switching. Switching from ETV to TAF is an effective strategy in CHB management, with hepatic inflammation potentially playing an essential role in achieving HBsAg decrease. Patients with increased Fib-4 index were significantly more likely to show decreased HBsAg. This finding suggests patients with mild to moderate fibrosis may respond better to TAF in terms of HBsAg reduction.<\/jats:p>","DOI":"10.3390\/v17010044","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T13:26:25Z","timestamp":1735651585000},"page":"44","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Decrease in HBsAg After TAF Switching from Entecavir During Long-Term Treatment of Chronic Hepatitis B Virus Infection"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2373-8601","authenticated-orcid":false,"given":"Kazuto","family":"Tajiri","sequence":"first","affiliation":[{"name":"Third Department of Internal Medicine, Faculty of Medicine, Academic Assembly, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, Faculty of Medicine, Academic Assembly, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiko","family":"Murayama","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, Faculty of Medicine, Academic Assembly, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomu","family":"Muraishi","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, Faculty of Medicine, Academic Assembly, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masami","family":"Minemura","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, Faculty of Medicine, Academic Assembly, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6888-0310","authenticated-orcid":false,"given":"Ichiro","family":"Yasuda","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, Faculty of Medicine, Academic Assembly, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S2468-1253(20)30307-1","article-title":"Estimating the proportion of people with chronic hepatitis B virus infection eligible for hepatitis B antiviral treatment worldwide: A systematic review and meta-analysis","volume":"6","author":"Tan","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"249","DOI":"10.35772\/ghm.2021.01078","article-title":"Messages from Japan policy for viral hepatitis","volume":"3","author":"Kanto","year":"2021","journal-title":"Glob. Health Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/S0140-6736(14)60220-8","article-title":"Hepatitis B virus infection","volume":"384","author":"Trepo","year":"2014","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/hep4.1436","article-title":"Durability of hepatitis B surface antigen loss with nucleotide analogue and peginterferon therapy in patients with chronic hepatitis B","volume":"4","author":"Lok","year":"2020","journal-title":"Hepatol. Commun."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jhep.2018.10.014","article-title":"HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues","volume":"70","author":"Yip","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jhep.2019.11.003","article-title":"Guidance for design and endpoints of clinical trials in chronic hepatitis B\u2014Report from the 2019 EASL-AASLD HBV Treatment endpoints conference","volume":"72","author":"Cornberg","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1053\/j.gastro.2019.01.015","article-title":"Hepatitis B Surface Antigen Loss: Too Little, Too Late and the Challenge for the Future","volume":"156","author":"Dusheiko","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Drafting Committee for Hepatitis Management Guidelines tJSoH (2020). Japan Society of Hepatology Guidelines for the Management of Hepatitis B Virus Infection: 2019 update. Hepatol. Res., 50, 892\u2013923.","DOI":"10.1111\/hepr.13504"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1002\/hep.21422","article-title":"Entecavir resistance is rare in nucleoside naive patients with hepatitis B","volume":"44","author":"Colonno","year":"2006","journal-title":"Hepatology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.cgh.2019.07.010","article-title":"Outcomes of long-term treatment of chronic HBV infection with entecavir or other agents from a randomized trial in 24 countries","volume":"18","author":"Hou","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_11","first-page":"324","article-title":"3-year Treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for chronic HBV infection in China","volume":"9","author":"Hou","year":"2021","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/jgh.12499","article-title":"Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment","volume":"29","author":"Fung","year":"2014","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","article-title":"96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection","volume":"68","author":"Agarwal","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1002\/jmv.25515","article-title":"Switching from entecavir to tenofovir alafenamide versus maintaining entecavir for chronic hepatitis B","volume":"91","author":"Hagiwara","year":"2019","journal-title":"J. Med. Virol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/apt.17107","article-title":"Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: Week 144 results from a real-world, multi-centre cohort study","volume":"56","author":"Ogawa","year":"2022","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1007\/s12072-023-10528-7","article-title":"Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: A systematic review and meta-analysis","volume":"17","author":"Hwang","year":"2023","journal-title":"Hepatol. Int."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Chien, R.N., and Liaw, Y.F. (2022). Current trend in antiviral therapy for chronic hepatitis B. Viruses, 14.","DOI":"10.3390\/v14020434"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1001\/jamaoncol.2018.4070","article-title":"Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B: A Korean Nationwide Cohort Study","volume":"5","author":"Choi","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Uchida, Y., Nakao, M., Yamada, S., Tsuji, S., Uemura, H., Kouyama, J.I., Naiki, K., Sugawara, K., Nakayama, N., and Imai, Y. (2022). Superiority of tenofovir alafenamide fumarate over entecavir for serum HBsAg level reduction in patients with chronic HBV infection: A 144-week outcome study after switching of the nucleos(t)ide analog. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0262764"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/jmv.25644","article-title":"Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate","volume":"92","author":"Uchida","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1111\/liv.14482","article-title":"Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B","volume":"40","author":"Ogawa","year":"2020","journal-title":"Liver Int."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/hepr.13650","article-title":"Comparison of efficacy and safety of entecavir and switching from entecavir to tenofovir alafenamide fumarate in chronic hepatitis B: Long-term effects from a prospective study","volume":"51","author":"Hagiwara","year":"2021","journal-title":"Hepatol. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e30630","DOI":"10.1097\/MD.0000000000030630","article-title":"Switching to tenofovir alafenamide versus continued therapy in chronic hepatitis B patients who were treated with entecavir: A prospective, multicenter, randomized controlled study","volume":"101","author":"Sato","year":"2022","journal-title":"Medicine"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"793","DOI":"10.3350\/cmh.2024.0252","article-title":"Non-linear association between liver fibrosis scores and viral load in patients with chronic hepatitis B","volume":"30","author":"Kim","year":"2024","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.21669","article-title":"FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest","volume":"46","author":"Mallet","year":"2007","journal-title":"Hepatology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/MNH.0000000000000971","article-title":"Has the time come for age-adapted glomerular filtration rate criteria to define chronic kidney disease: How soon is now?","volume":"33","author":"Hundemer","year":"2024","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"101851","DOI":"10.1016\/j.beem.2023.101851","article-title":"The pathophysiology of hypophosphatemia","volume":"38","author":"Ito","year":"2024","journal-title":"Best. Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/hepr.14056","article-title":"A nation-wide medical record database study: Value of hepatitis B surface antigen loss in chronic hepatitis B patients in Japan","volume":"54","author":"Okada","year":"2024","journal-title":"Hepatol. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/hep.26277","article-title":"Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load","volume":"58","author":"Gordon","year":"2013","journal-title":"Hepatology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1136\/gutjnl-2014-308353","article-title":"Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: Results of a randomised trial","volume":"65","author":"Lim","year":"2016","journal-title":"Gut"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jhep.2019.02.021","article-title":"Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial","volume":"71","author":"Lim","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1136\/gutjnl-2014-308435","article-title":"Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: Results of a randomised trial","volume":"65","author":"Lim","year":"2016","journal-title":"Gut"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa1708131","article-title":"Tenofovir versus Placebo to Prevent Perinatal Transmission of Hepatitis B","volume":"378","author":"Jourdain","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_34","first-page":"370","article-title":"No difference in hepatocellular carcinoma risk between chronic hepatitis B patients treated with entecavir versus tenofovir","volume":"70","author":"Su","year":"2021","journal-title":"Gut"},{"key":"ref_35","first-page":"3032","article-title":"Tenofovir versus entecavir on the prognosis of hepatitis B-related hepatocellular carcinoma after surgical resection: A randomised controlled trial","volume":"109","author":"He","year":"2023","journal-title":"Int. J. Surg."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: A randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Buti","year":"2016","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: A randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Chan","year":"2016","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S2468-1253(19)30421-2","article-title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: A randomised, double-blind, phase 3, multicentre non-inferiority study","volume":"5","author":"Lampertico","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1517\/14740331003627458","article-title":"Renal toxicity associated with tenofovir use","volume":"9","author":"Alvarez","year":"2010","journal-title":"Expert. Opin. Drug Saf."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.14309\/ajg.0000000000001157","article-title":"Outcomes of sequential therapy with tenofovir alafenamide after long-term entecavir","volume":"116","author":"Nguyen","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/apt.17785","article-title":"Increased spine bone density in patients with chronic hepatitis B switched to tenofovir alafenamide: A prospective, multinational study","volume":"59","author":"Ogawa","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1002\/hep.27654","article-title":"High liver fibrosis index FIB-4 is highly predictive of hepatocellular carcinoma in chronic hepatitis B carriers","volume":"61","author":"Suh","year":"2015","journal-title":"Hepatology"},{"key":"ref_43","first-page":"649","article-title":"Non-linear association of baseline viral load with on-treatment hepatocellular carcinoma risk in chronic hepatitis B","volume":"73","author":"Choi","year":"2024","journal-title":"Gut"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1136\/gutjnl-2016-312653","article-title":"Induction of IFN-lambda3 as an additional effect of nucleotide, not nucleoside, analogues: A new potential target for HBV infection","volume":"67","author":"Murata","year":"2018","journal-title":"Gut"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1002\/hep.30956","article-title":"Immunomodulatory mechanism of acyclic nucleoside phosphates in treatment of hepatitis B virus infection","volume":"71","author":"Murata","year":"2020","journal-title":"Hepatology"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/1\/44\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:57:40Z","timestamp":1760115460000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/1\/44"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,31]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["v17010044"],"URL":"https:\/\/doi.org\/10.3390\/v17010044","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,31]]}}}